IL22RA1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07055(IL22RA1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07055(IL22RA1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The IL22RA1 antibody targets the interleukin-22 receptor alpha 1 (IL22RA1), a key subunit of the IL-22 receptor complex. IL22RA1 is a member of the type II cytokine receptor family and pairs with IL-10Rβ to form a functional receptor for IL-22. a cytokine involved in mucosal immunity, tissue repair, and inflammatory responses. IL-22 signaling through IL22RA1 activates downstream pathways like JAK/STAT, particularly STAT3. regulating epithelial cell proliferation, barrier function, and antimicrobial peptide production.

IL22RA1 is primarily expressed on epithelial cells, fibroblasts, and certain immune cells. Its role in diseases has drawn significant interest; dysregulated IL-22/IL22RA1 signaling is linked to autoimmune disorders (e.g., psoriasis, inflammatory bowel disease), chronic inflammation, and cancer. In cancer, IL22RA1 overexpression may promote tumor progression by enhancing cell survival and tissue remodeling.

Antibodies against IL22RA1 are vital tools for research and therapeutic development. They enable detection of receptor expression in tissues, block IL-22 signaling in experimental models, and help evaluate the receptor’s role in pathogenesis. Therapeutic antibodies targeting IL22RA1 are being explored to modulate IL-22 activity in diseases where its pathway is overactive. However, challenges remain in balancing efficacy with potential side effects, as IL-22 also has protective roles in barrier integrity and wound healing. Studies using IL22RA1 antibodies continue to clarify its dual functions in health and disease.